FDA Grants Compassionate Use Approval for OKYO’s Urcosimod in Neuropathic Corneal Pain
Event summary
- FDA authorized compassionate use of urcosimod (0.05%) for a single patient with severe neuropathic corneal pain (NCP) under IND 176297.
- OKYO Pharma’s urcosimod is the first investigational therapy granted IND for NCP and has fast track designation.
- Company plans to initiate a 120-patient Phase 2b/3 trial for NCP in 2026.
- Urcosimod showed statistical significance in a Phase 2 trial involving 18 NCP patients.
The big picture
OKYO Pharma’s FDA authorization for compassionate use of urcosimod underscores the critical unmet need in treating neuropathic corneal pain, a condition with no approved therapies. The move aligns with broader industry trends toward targeted therapies for rare and debilitating eye diseases, where regulatory agencies are increasingly granting fast-track designations to expedite development. The company’s planned Phase 2b/3 trial could further validate urcosimod’s dual mechanism of action, potentially positioning it as a cornerstone treatment in this niche but growing therapeutic area.
What we're watching
- Clinical Execution
- Whether OKYO can successfully initiate and complete the Phase 2b/3 trial for NCP in 2026.
- Regulatory Pathway
- The pace at which the FDA may accelerate approval pathways for urcosimod given its fast track designation.
- Commercial Potential
- How early compassionate use approvals could position urcosimod as a potential first-in-class therapy for NCP.
Related topics